IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

3 years ago

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor typesNEW YORK,…

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra

3 years ago

Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

Remix Therapeutics to Present at 4th Annual RNA-Targeted Drug Discovery Summit

3 years ago

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram…

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

3 years ago

WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein…

Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

3 years ago

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel…

H-CYTE Names Michael Yurkowsky Chief Executive Officer

3 years ago

TAMPA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of…

DLH Reports Fiscal 2021 Fourth Quarter Results

3 years ago

Q4 Revenue of $65.2 Million; Full Year Revenue $246.1 Million, up 17.6% over fiscal 2020; Debt Reduced to $46.8 MillionATLANTA,…

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

3 years ago

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing…

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

3 years ago

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,…

Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

3 years ago

Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicanna’s self-emulsifying drug delivery systems (SEDDS)…